Mediwound (NASDAQ:MDWD) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01), Morningstar.com reports. Mediwound had a negative return on equity of 398.49% and a negative net margin of 31.08%.
Shares of MDWD stock opened at $4.17 on Wednesday. Mediwound has a 1-year low of $3.76 and a 1-year high of $7.35. The firm has a market cap of $113.34 million, a PE ratio of -8.51 and a beta of 0.70.
Several hedge funds have recently modified their holdings of the company. Morgan Stanley grew its stake in shares of Mediwound by 65.6% in the first quarter. Morgan Stanley now owns 36,584 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 14,489 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Mediwound in the first quarter worth $93,000. Renaissance Technologies LLC grew its stake in shares of Mediwound by 45.0% in the first quarter. Renaissance Technologies LLC now owns 328,700 shares of the biopharmaceutical company’s stock worth $1,644,000 after purchasing an additional 102,060 shares during the last quarter. Delek Group Ltd. bought a new stake in shares of Mediwound in the first quarter worth $141,000. Finally, Meitav Dash Investments Ltd. grew its stake in shares of Mediwound by 0.6% in the first quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after purchasing an additional 3,536 shares during the last quarter. Institutional investors and hedge funds own 30.29% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Mediwound (MDWD) Releases Earnings Results, Misses Estimates By $0.01 EPS” was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://dakotafinancialnews.com/2019/05/22/mediwound-mdwd-releases-earnings-results-misses-estimates-by-0-01-eps.html.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Story: What economic reports are most valuable to investors?
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.